<DOC>
	<DOCNO>NCT00406497</DOCNO>
	<brief_summary>The purpose phase 2 study determine difluprednate ophthalmic emulsion effective treatment postoperative inflammation .</brief_summary>
	<brief_title>Study Difluprednate Ophthalmic Emulsion Treatment Postoperative Inflammation</brief_title>
	<detailed_description>The objective ass efficacy endpoint comparison 0.1 % BM ophthalmic solution , prior investigation efficacy safety 0.05 % DFBA ophthalmic emulsion treatment postoperative intraocular inflammation .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Difluprednate</mesh_term>
	<mesh_term>Fluprednisolone</mesh_term>
	<criteria>Patients undergo intraocular surgery ( cataract surgery , cataract surgery + implantation intraocular lens , vitreous surgery , cataract surgery + implantation intraocular lens + vitreous surgery ) Patients anterior chamber cell score ≥2 next day surgery Male female patient age ≥20 year ( day obtain informed consent ) Patients give write informed consent prior initiation study Patients meet inclusion criterion Patients receive systemic administration corticosteroid immunosuppressive drug , topical application corticosteroid ophthalmic ointment within 1 week instillation investigational product Patients receive topical injection corticosteroid eye instillation investigational product ( aqueous preparation : within 1 week instillation investigational product , depot preparation : within 2 week instillation investigational product ) Patients receive systemic administration nonsteroidal antiinflammatory drug antiphlogistic enzyme Patients receive instillation corticosteroid , nonsteroidal antiinflammatory ophthalmic solution antiphologistic enzyme within 24 hour ophthalmic examination prior instillation investigational product ( next day surgery ) ( except instillation nonsteroidal antiinflammatory ophthalmic solution 3 , 2 , 1 0.5 hour surgery ) Patients endogenous uveitis Patients plan undergo surgery contralateral eye study period Patients new intraocular bleeding surgery Patients receive gas silicon oil vitreous body Patients glaucoma ocular hypertension ( IOP next day surgery ≥25 mmHg ) Patients superficial punctuate keratopathy corneal ulcer Patients viral , bacterial fungal keratoconjunctival disease Patients allergy corticosteroid Patients require use contact lens study period Women might pregnant , lactate woman Patients participate another clinical study within 3 month initiation present study Patients undergo surgery systemic anesthesia</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>